Abstract
In the present study we compared effects of the competitive and non-competitive NMDA antagonists CGP 37849 and MK-801, respectively, on sensorimotor gating in rats, measured as prepulse-induced inhibition of the acoustic startle response, and the outflow of dopamine in the rat prefrontal cortex. CGP 37849 (10, 20 mg/kg), decreased the amplitude of the acoustic startle response, but was without effect on the prepulse-induced inhibition of the acoustic startle response. MK-801 (0.4 but not 0.2 mg/kg) enhanced the amplitude of the acoustic startle response and its doses of 0.2 and 0.4 mg/kg markedly attenuated the prepulse-induced inhibition of the acoustic startle response. The effects of MK-801 (0.4 mg/kg) on the prepulse-induced inhibition of the acoustic startle response were not antagonized by the selective antagonists of D-2 and D-1 dopaminergic receptors, S(−)sulpiride (25 mg/kg) and SCH 23390 (0.1 mg/kg), respectively. When given alone, S(−)sulpiride attenuated the amplitude of the acoustic startle response and failed to altered the prepulse-induced inhibition of the acoustic startle response. SCH 23390 (0.1 mg/kg) failed to alter the amplitude and prepulse-induced inhibition of the acoustic startle response. The effects of CGP 37849 and MK-801 also differed with respect to dopamine outflow. MK-801 (0.2 and 0.4 mg/kg) enhanced the outflow of dopamine in the rat prefronatl cortex, while CGP 37849 (10 and 20 mg/kg) was without any effect on the extracellular concentration of dopamine. Our data indicate that the blockade of phencyclidine binding sites, exerted by the noncompetitive antagonist MK-801, evoked effects qualitatively different from those induced — via blockade of the NMDA recognition — by the competitive NMDA receptor antagonist CGP 37849. It is postulated that — in contrast to the non-competitive antagonist of NMDA receptors — the competitive NMDA antagonist CGP 37849 is/ should be devoid of psychotomimetic and abusing properties. It is also evident that disruption of sensorimotor gating in rats induced by MK-801 does not involve any dopaminergic mechanisms, since it is not modulated by drugs blocking D-1 and D-2 dopamine receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia: Human and animal model studies. Arch Gen Psychiatry 40:181–188
Bubser M, Koch M (1994) Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmcology (Berl) 113:487–492
Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and noncompetitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75–82
Evans RH, Francis AA, Jones AW, Smith DA, Watkins JC (1982) The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol 75:65–75
Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P., Thedinga K, Bittiger H (1990) CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol 99:791–797
French ED, Ceci A (1990) Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci Lett 119:159–162
French ED, Ferkany J, Abreu M, Levenson S (1991) Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neurpharmacology 30:1039–1046
Geyer MA, Braff DL (1990) Dopaminergic effects of LSD on an animal model of sensorimotor gating deficits in schizophrenia. Biol Psychiatry 27:97A
Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485–498
Goldstein M, Deutch AY (1992) Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 6:2413–2421
Gonon FG, Buda MJ (1985) Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltammetry in the rat striatum. Neuroscience 14:765–774
Hoffman DC, Donovan H, Cassella JV (1993) The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology 111:339–344
Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555–556
Keefe KA, Zigmond MJ, Abercrombie ED (1993) In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids. J Neural Transm Gen Sect 91:223–240
Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557–566
Kiss JP, Toth E, Lajtha A, Vizi ES (1994) NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: a microdialysis study. Brain Res 641:145–148
Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28:539–546
Krase W, Koch M, Schnitzler H-U (1993) Glutamate antagonists in the reticular formation reduce the acoustic startle response. NeuroReport 4:13–16
Liljequist S, Ossowska K, Grabowska Anden M, Anden NE (1991) Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 19. 195:55–61
Löscher W, Hönack D (1991) The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin 1A receptors. J Pharmacol Exp Ther 257:1146–1153
Maj J, Rogoz Z, Skuza G (1991) Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J Neural Trans Gen Sect 85:169–179
Maj J, Rogoz Z, Skuza G (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J Neural Transm [P-D Sect] 6:53–62
Mansbach RS (1991) Effects of NMDA, receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 202:61–66
Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299–308
Mehta AK, Ticku MK (1990) Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci 46:37–42
Meldrum BS (1985) Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 68:113–122
Miller CL, Bickford PC, Luntz Leybman V, Adler LE, Gerhardt GA, Freedman R (1992) Phencyclidine and auditory sensory gating in the hippocampus of the rat. Neuropharmacology 31:1041–1048
Moghaddam B, Bunney BS (1989) Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53;:652–654
Mount H, Boksa P, Chaudieu L, Quirion R (1990) Phencyclidine and related compounds evoked [3H]dopamine release from rat mesencephalic cell cultures by a mechanism independent of the phencyclidine receptor, sigma binding site, or dopamine uptake site. Can J Physiol Pharmacol 68:1200–1206
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, Academic Press, San Diego
Pozza MIT, Olpe HR, Brugger F, Fagg GE (1990) Electrophysiological characterization of a novel potent and orally active NMDA receptor antagonist: CGP 37849 and its ethylester CGP 39551. Eur J Pharmacol 182:91–100
Rao TS, Cler JA, Mick SJ, Emmett MR, Farah JM Jr., Contreras PC, Iyengar S, Wood PL (1991 a) Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway. J Neurochem 56:907–913
Rao TS, Contreras PC, Cler JA, Mick SJ, Dilworth VM, Iyengar S, Monahan JB, Wood PL (1991 b) Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites. J Neurochem 56:890–897
Rogawski MA (1992) NMDA receptor, NMDA antagonists and epilepsy therapy. A status report. Drugs 44:279–292
Richter A, Fredow G, Loscher W (1991) Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. Neurosci Lett 133:57–60
Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621–623
Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, Heckendorn R, Fagg GE, Olpe HR, van Riezen H (1990) The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedeberg's Arch Pharmacol 342:61–66
Spiera RF, Davis M (1988) Excitatory amino acid antagonists depress acoustic startle after infusion into the ventral nucleus of the lateral lemniscus or paralemniscal zone. Brain Res 445:130–136
Svensson A, Pileblad E, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Trans Gen Sect 85:117–129
Swerdlow NR, Braff DL, Masten VL, Geyer MA (1990a) Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology (Berl) 101:414–420
Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL (1990b) Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl) 100:413–416
Tiedtke PI, Bischoff C, Schmidt WJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Trans Gen Sect 81:173–182
Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127–135
Wędzony K, Golembiowska K, Klimek V (1993a) MK-801-induces symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Res 625:333–336
Wędzony K, Klimek V, Golembiowska K (1993b) MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of straiatl dopamine D1 receptors. Brain Res 622:325–329
Willetts J, Balster RL, Leander JD (1990) The behavioural pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11: 423–428
Wong EH, Knight AR, Woodruff GN (1988) [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 50:274–281
Zhang J, Chiodo LA, Freeman AS (1992) Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res 590:153–163
Author information
Authors and Affiliations
Additional information
Correspondence to: K. Wędzony at the above address
Rights and permissions
About this article
Cite this article
Wędzony, K., Gołembiowska, K. & Zazula, M. Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn-Schmiedeberg's Arch Pharmacol 350, 555–562 (1994). https://doi.org/10.1007/BF00173026
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00173026